Business
Citius Oncology Expands LYMPHIR™ Distribution to Turkey and Middle East Countries Through Exclusive Agreement with Er-Kim
Partnership expands access to LYMPHIR for patients with cutaneous T-cell lymphoma across Turkey, Bahrain, Qatar, Oman, Kuwait, Saudi Arabia, and the
About this update from Citius Pharmaceuticals, Inc.
[{"type":"text","content":"Partnership expands access to LYMPHIR for patients with cutaneous T-cell lymphoma across Turkey, Bahrain, Qatar, Oman, Kuwait, Saudi Arabia, and the UAELYMPHIR international availability extends to 19 markets outside the U.S.CRANFORD, N.J., Dec. 4, 2025 /PRNewswire/ -- Citius Oncology, Inc. (\"Citius Oncology\") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. (\"Citius Pharma\") (Nasdaq: CTXR), today announced that it has entered into an exclusive distribution agreement with Er-Kim İlaç Sanayi ve Ticaret A.Ş. (\"Er-Kim\"), a leading pharmaceutical distributor based in Turkey, for LYMPHIR (denileukin diftitox-cxdl), a novel IL-2 receptor-directed cytotoxin, approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with relapsed or refractory Stage I-III cutaneous T-cell lymphoma after at least one prior systemic therapy. Under the terms of the agreement, Er-Kim will be the exclusive distributor of LYMPHIR in Turkey and key Gulf Cooperation Council (GCC) countries, including Bahrain, Qatar, Oman, Kuwait, Saudi Arabia, and the United Arab Emirates.\n \n \n \n \n \n \n \nThe agreement expands Citius Oncology's international strategy to a total of 19 markets outside the U.S. leveraging Named Patient Programs. These programs provide access, where permitted by local law, and do not constitute commercial approval of LYMPHIR outside the United States. In October 2025, Citius Oncology announced access to LYMPHIR in Greece, Cyprus, Malta, Bulgaria, Romania, Croatia, Serbia, Albania, Bosnia Herzegovina, Kosovo, Montenegro and North Macedonia.\"This agreement represents a significant milestone in our global expansion strategy,\" said Leonard Mazur, Chairman and CEO of Citius Oncology and Citius Pharmaceuticals. \"Er-Kim has deep industry experience and a strong track record of providing access to oncology therapies in complex international markets. Their local expertise and regulatory capabilities make them an ideal partner as we work to expand access to LYMPHIR in support of patients and providers across Turkey and the GCC.\"Er-Kim will be responsible for sales, marketing and reimbursement activities, under applicable laws, in each territory. Citius Oncology will supply finished product and support Er-Kim's efforts as part of the agreement.This partnership underscores Citius ...